Switch theme
Sign up to access all valuation multiples
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
2011
423
LTM Revenue $68.9M
LTM EBITDA -$40.5M
$163M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sophia Genetics has a last 12-month revenue (LTM) of $68.9M and a last 12-month EBITDA of -$40.5M.
In the most recent fiscal year, Sophia Genetics achieved revenue of $65.2M and an EBITDA of -$50.8M.
Sophia Genetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sophia Genetics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $68.9M | XXX | $65.2M | XXX | XXX | XXX |
| Gross Profit | $47.6M | XXX | $43.9M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | -$40.5M | XXX | -$50.8M | XXX | XXX | XXX |
| EBITDA Margin | -59% | XXX | -78% | XXX | XXX | XXX |
| EBIT | -$50.7M | XXX | -$66.6M | XXX | XXX | XXX |
| EBIT Margin | -74% | XXX | -102% | XXX | XXX | XXX |
| Net Profit | -$61.6M | XXX | -$62.5M | XXX | XXX | XXX |
| Net Margin | -89% | XXX | -96% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sophia Genetics's stock price is $3.
Sophia Genetics has current market cap of $201M, and EV of $163M.
See Sophia Genetics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $163M | $201M | XXX | XXX | XXX | XXX | $-0.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sophia Genetics has market cap of $201M and EV of $163M.
Sophia Genetics's trades at 2.5x EV/Revenue multiple, and -3.2x EV/EBITDA.
Equity research analysts estimate Sophia Genetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sophia Genetics has a P/E ratio of -3.3x.
See valuation multiples for Sophia Genetics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $201M | XXX | $201M | XXX | XXX | XXX |
| EV (current) | $163M | XXX | $163M | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | -4.0x | XXX | -3.2x | XXX | XXX | XXX |
| EV/EBIT | -3.2x | XXX | -2.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.3x | XXX | -3.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSophia Genetics's last 12 month revenue growth is 18%
Sophia Genetics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Sophia Genetics's rule of 40 is -94% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sophia Genetics's rule of X is -14% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sophia Genetics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | -59% | XXX | -78% | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -94% | XXX | -60% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -14% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 170% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Beamtree | XXX | XXX | XXX | XXX | XXX | XXX |
| Cogstate | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| Impedimed | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sophia Genetics acquired XXX companies to date.
Last acquisition by Sophia Genetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Sophia Genetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sophia Genetics founded? | Sophia Genetics was founded in 2011. |
| Where is Sophia Genetics headquartered? | Sophia Genetics is headquartered in United States of America. |
| How many employees does Sophia Genetics have? | As of today, Sophia Genetics has 423 employees. |
| Who is the CEO of Sophia Genetics? | Sophia Genetics's CEO is Dr. Jurgi Camblong, M.B.A.,PhD. |
| Is Sophia Genetics publicy listed? | Yes, Sophia Genetics is a public company listed on NAS. |
| What is the stock symbol of Sophia Genetics? | Sophia Genetics trades under SOPH ticker. |
| When did Sophia Genetics go public? | Sophia Genetics went public in 2021. |
| Who are competitors of Sophia Genetics? | Similar companies to Sophia Genetics include e.g. Beamtree, Cogstate, Echo IQ, Impedimed. |
| What is the current market cap of Sophia Genetics? | Sophia Genetics's current market cap is $201M |
| What is the current revenue of Sophia Genetics? | Sophia Genetics's last 12 months revenue is $68.9M. |
| What is the current revenue growth of Sophia Genetics? | Sophia Genetics revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Sophia Genetics? | Current revenue multiple of Sophia Genetics is 2.4x. |
| Is Sophia Genetics profitable? | Yes, Sophia Genetics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sophia Genetics? | Sophia Genetics's last 12 months EBITDA is -$40.5M. |
| What is Sophia Genetics's EBITDA margin? | Sophia Genetics's last 12 months EBITDA margin is -59%. |
| What is the current EV/EBITDA multiple of Sophia Genetics? | Current EBITDA multiple of Sophia Genetics is -4.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
